TY  - CHAP
M1  - Book, Section
TI  - Carcinoma of the Female Breast
A1  - Giuliano, Armando E.
A1  - Hurvitz, Sara A.
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - KEY  CLINICAL  UPDATES  IN  CARCINOMA  OF  THE  FEMALE  BREASTIn  2020,  the  FDA  approved  neratinib  (in  combination  with  capecitabine)  and  margetuximab,  a  monoclonal  antibody  similar  to  trastuzumab  that  is  designed  to  improve  the  antibody  dependent  cellular  cytotoxicity  mechanism  of  action  when  used  with  chemotherapy.In  2020,  pembrolizumab,  a  second  immune  checkpoint  inhibitor,  was  FDA  approved  for  use  in  patients  with  PD-L1  positive  disease  in  combination  with  chemotherapy  (taxane  or  gemcitabine/carboplatin)  based  on  results  from  the  KEYNOTE  355  trial  showing  an  improved  median  progression-free  survival  with  the  addition  of  this  antibody  to  standard  chemotherapy.Sacituzumab  govitecan  (TRODELVY)  is  the  first  antibody  drug  conjugate  approved  for  triple  negative  breast  cancer.The  phase  3  confirmatory  trial,  ASCENT,  demonstrated  that  sacituzumab  govitecan  is  associated  with  a  statistically  significant  improvement  in  progression-free  and  overall  survival  when  compared  to  single-agent  chemotherapy  in  patients  with  triple  negative  breast  cancer  who  had  received  at  least  two  prior  lines  of  standard  chemotherapy  for  metastatic  disease.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/23
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184174934
ER  -